nAMD Treatment: The Eylea Treat-and-Extend Approach

In this video, the flexible dosing approach for treating neovascular age-related macular degeneration (nAMD) with Eylea was explained. The treat-and-extend protocol, approved based on results of the Phase 4 ALTAIR study, begins with 3 monthly injections, followed by a 2-month interval, with further adjustments based on four clinical criteria, i.e. vision loss, increased retinal thickness, new neovascularisation or macular haemorrhage. This approach allows proactive, personalised interval adjustments while tolerating stable residual fluid to prevent under- or overtreatment, enabling patients to benefit from effective treatment with reduced injection frequency and greater convenience.